Home » Sarc Sarcoma Spore » Developmental Research Grant Recipients
SARC awarded the following investigators and projects SARC Developmental Research Grants. A component of the SARC Sarcoma SPORE was funding for developmental research projects (2012–2016).
Duke University Medical Center Mechanisms that Regulate Sarcoma Response to Immune Checkpoint Inhibition of PD1
Baylor College of Medicine The Metastatic Role of Lysyl Oxidase in Osteosarcoma
University of Southern California Immune Profiling in Well Differentiated/Dedifferentiated Liposarcoma
University of Michigan Can heart disease be predicted in young survivors of osteosarcoma using morphomics and/or coronary artery calcium scores?
Duke University Medical Center Mechanisms that regulate sarcoma response to immune checkpoint Inhibition of PD1
Fred Hutchinson Cancer Research Center Designing improved T-cell therapies for sarcoma patients
Cleveland Clinic Foundation Identification of prognostic and therapeutic biomarkers in epithelioid hemangioendothelioma
Massaschusetts General Hospital Computer-aided estimation of tumor viability fractions on MRI to facilitate procurement of negative surgical resection margins of musculoskeletal sarcoma
Massachusetts General Hospital Dissecting CDK11 kinase pathway in osteosarcoma
Brigham & Women’s Hospital Biomarkers for Dystrophin-deficiency in sarcoma
Oregon Health & Science University
Massachusetts General Hospital GSK3-beta inhibitors for relapsed rhabdomyosarcom
Duke University Medical Center Translating discoveries from a mouse model into metastatic biomarker
University of Utah Huntsman Cancer Institute Epigenetic targeting of LSD1 as a therapeutic strategy for Ewing sarcoma
Massachusetts General Hospital GSK3-beta inhibitors for relapsed rhabdomyosarcoma
Duke University Medical Center Translating discoveries from a mouse model into metastatic biomarkers
University of Utah Huntsman Cancer Center Epigenetic targeting of LSD1 as a therapeutic strategy for Ewing sarcoma
Georgia Regents University
Ohio State University Combined radiosensitization and T cell immunotherapy for metastatic sarcoma